Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts - Benzinga
Sage Therapeutics' (SAGE) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from HC Wainwright - MarketBeat
Sage Therapeutics (NASDAQ:SAGE) Receives Hold Rating from Needham & Company LLC - MarketBeat
Sage Therapeutics' (SAGE) "Hold" Rating Reiterated at Needham & Company LLC - MarketBeat
Canaccord cuts Sage Therapeutics price target to $8, holds rating - Investing.com
Sage Therapeutics (SAGE) PT Lowered to $12 at H.C. Wainwright - StreetInsider.com
Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties - TipRanks
Sage Therapeutics (SAGE) PT Lowered to $12 at H.C. Wainwright - StreetInsider.com
SAGE Therapeutics: Hold Rating Amid Uncertainty and Strategic Exploration - TipRanks
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »
×